There is actually 70 m savings in operating expenses , so Mayne is operating both Nexstellis and TXMD at profit for the first time , so they are correct 14 m +ve contribution and international segment always making profit , hopefully they add more dermatology products from similar companies to use the existing sales force . Smart idea
Exciting news for Mayne Pharma new addition investors, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.08 |
Change
0.010(0.20%) |
Mkt cap ! $412.7M | |||
| Open | High | Low | Value | Volume |
| $5.05 | $5.08 | $5.02 | $395.8K | 78.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $5.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.08 | 3084 | 3 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| MYX (ASX) Chart |